Purple Biotech Ltd. (IL:PPBT)
TASE:PPBT
Want to see IL:PPBT full AI Analyst Report?
PPBT Stock Chart & Stats
1.20
>-0.01(-5.19%)
At close: 4:00 PM EST
1.20
>-0.01(-5.19%)
Day’s Range― - ―
52-Week Range1.00 - 5.70
Previous CloseN/A
Volume1.16M
Average Volume (3M)8.90M
Market Cap
₪20.26M
Enterprise Value-3.52M
Total Cash (Recent Filing)₪6.49M
Total Debt (Recent Filing)₪185.77K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding2,026,127,600
10 Day Avg. Volume1,387,469
30 Day Avg. Volume8,902,795
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Financial FlexibilityVery low debt gives the company structural financial flexibility at a clinical stage. With limited interest burden, management can prioritize R&D spend and negotiate partner deals without heavy refinancing pressure, supporting sustained operations while pursuing trials.
Promising Lead Candidate (IM1240)Robust preclinical responses across treatment-resistant patient-derived tumors indicate a differentiated mechanism and translational potential. Durable pipeline progress on a tri-specific platform can underpin long-term value, attract partners, and de-risk later-stage development if clinical efficacy follows.
Access To Capital Via Shelf FilingA $200M mixed securities shelf establishes structural capacity to raise equity/debt or issue securities over time. For a cash-burning clinical biotech, this provides an organized, long-dated mechanism to fund trials, partnerships, or acquisitions without emergency financings.
Bears Say
Large Recurring LossesSustained, sizable operating losses with essentially no product revenue indicate the company remains pre-commercial and dependent on milestones or financing. Over months this depletes capital, constrains strategic choices, and raises execution risk until clinical or partnership milestones materialize.
Negative Cash GenerationPersistent negative operating and free cash flows mean the company is burning cash to fund R&D. Even with some improvement, ongoing outflows make the business reliant on external funding, increasing dilution risk and pressuring timely delivery of clinical readouts or partner payments.
Shrinking Equity And Asset BaseA materially reduced equity and asset base lowers the financial cushion against adverse outcomes and elevates financing risk. With less internal capital, future fundraises may be more dilutive and the company is more sensitive to missed milestones or unfavorable market conditions.
Purple Biotech News
PPBT FAQ
What was Purple Biotech Ltd.’s price range in the past 12 months?
Purple Biotech Ltd. lowest stock price was 1.00 and its highest was 5.70 in the past 12 months.
What is Purple Biotech Ltd.’s market cap?
Purple Biotech Ltd.’s market cap is ₪20.26M.
When is Purple Biotech Ltd.’s upcoming earnings report date?
Purple Biotech Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Purple Biotech Ltd.’s earnings last quarter?
Purple Biotech Ltd. released its earnings results on May 15, 2026. The company reported 0 earnings per share for the quarter, the consensus estimate of N/A by 0.
Is Purple Biotech Ltd. overvalued?
According to Wall Street analysts Purple Biotech Ltd.’s price is currently Overvalued.
Does Purple Biotech Ltd. pay dividends?
Purple Biotech Ltd. pays a Notavailable dividend of 249.549 which represents an annual dividend yield of N/A. See more information on Purple Biotech Ltd. dividends here
What is Purple Biotech Ltd.’s EPS estimate?
Purple Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Purple Biotech Ltd. have?
Purple Biotech Ltd. has 2,026,127,600 shares outstanding.
What happened to Purple Biotech Ltd.’s price movement after its last earnings report?
Purple Biotech Ltd. reported an EPS of 0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Purple Biotech Ltd.?
Currently, no hedge funds are holding shares in IL:PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.